Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics
- Author(s)
- Doig, KD; Love, CG; Conway, T; Seleznev, A; Ma, D; Fellowes, A; Blombery, P; Fox, SB;
- Journal Title
- BMC Medical Genomics
- Publication Type
- Research article
- Abstract
- BACKGROUND: Next generation sequencing for oncology patient management is now routine in clinical pathology laboratories. Although wet lab, sequencing and pipeline tasks are largely automated, the analysis of variants for clinical reporting remains largely a manual task. The increasing volume of sequencing data and the limited availability of genetic experts to analyse and report on variants in the data is a key scalability limit for molecular diagnostics. METHOD: To determine the impact and size of the issue, we examined the longitudinally compiled genetic variants from 48,036 cancer patients over a six year period in a large cancer hospital from ten targeted cancer panel tests in germline, solid tumour and haematology contexts using hybridization capture and amplicon assays. This testing generated 24,168,398 sequenced variants of which 23,255 (8214 unique) were clinically reported. RESULTS: Of the reported variants, 17,240 (74.1%) were identified in more than one assay which allowed curated variant data to be reused in later reports. The remainder, 6015 (25.9%) were not subsequently seen in later assays and did not provide any reuse benefit. The number of new variants requiring curation has significantly increased over time from 1.72 to 3.73 variants per sample (292 curated variants per month). Analysis of the 23,255 variants reported, showed 28.6% (n = 2356) were not present in common public variant resources and therefore required de novo curation. These in-house only variants were enriched for indels, tumour suppressor genes and from solid tumour assays. CONCLUSION: This analysis highlights the significant percentage of variants not present within common public variant resources and the level of non-recurrent variants that consequently require greater curation effort. Many of these variants are unique to a single patient and unlikely to appear in other patients reflecting the personalised nature of cancer genomics. This study depicts the real-world situation for pathology laboratories faced with curating increasing numbers of low-recurrence variants while needing to expedite the process of manual variant curation. In the absence of suitably accurate automated methods, new approaches are needed to scale oncology diagnostics for future genetic testing volumes.
- Keywords
- Genomics/methods; High-Throughput Nucleotide Sequencing/methods; Humans; *Neoplasms/diagnosis/genetics/pathology; Pathology, Molecular; Precision Medicine/methods; Clinical sequencing; Genomic database; Molecular diagnostics; Ngs; Precision medicine; Precision oncology; Variant analysis
- Department(s)
- Pathology; Haematology
- PubMed ID
- 35346197
- Publisher's Version
- https://doi.org/10.1186/s12920-022-01214-y
- Open Access at Publisher's Site
https://doi.org/10.1186/s12920-022-01214-y- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-24 01:11:59
Last Modified: 2024-10-24 01:14:10